Murray, Warren Hit Trump Administration For Criticizing 340B While Backing Away From Rule, Guidance

May 15, 2018
Senate health committee ranking Democrat Patty Murray (WA) and Sen. Elizabeth Warren (D-MA) on Tuesday (May 15) criticized President Donald Trump for tying the 340B program to higher drug prices while his administration has repeatedly delayed implementation of a rule on ceiling prices and manufacturer penalties and pulled back guidance to clarify aspects of the program, including the definition of a 340B-eligible patient. “President Trump can talk and tweet about lowering drug prices all he wants, but when his only...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.